Correlation Between Lineage Cell and Passage Bio
Can any of the company-specific risk be diversified away by investing in both Lineage Cell and Passage Bio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lineage Cell and Passage Bio into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lineage Cell Therapeutics and Passage Bio, you can compare the effects of market volatilities on Lineage Cell and Passage Bio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lineage Cell with a short position of Passage Bio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lineage Cell and Passage Bio.
Diversification Opportunities for Lineage Cell and Passage Bio
-0.38 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Lineage and Passage is -0.38. Overlapping area represents the amount of risk that can be diversified away by holding Lineage Cell Therapeutics and Passage Bio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Passage Bio and Lineage Cell is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lineage Cell Therapeutics are associated (or correlated) with Passage Bio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Passage Bio has no effect on the direction of Lineage Cell i.e., Lineage Cell and Passage Bio go up and down completely randomly.
Pair Corralation between Lineage Cell and Passage Bio
Given the investment horizon of 90 days Lineage Cell Therapeutics is expected to generate 1.8 times more return on investment than Passage Bio. However, Lineage Cell is 1.8 times more volatile than Passage Bio. It trades about 0.08 of its potential returns per unit of risk. Passage Bio is currently generating about -0.49 per unit of risk. If you would invest 59.00 in Lineage Cell Therapeutics on November 4, 2024 and sell it today you would earn a total of 4.00 from holding Lineage Cell Therapeutics or generate 6.78% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Lineage Cell Therapeutics vs. Passage Bio
Performance |
| Timeline |
| Lineage Cell Therapeutics |
| Passage Bio |
Lineage Cell and Passage Bio Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Lineage Cell and Passage Bio
The main advantage of trading using opposite Lineage Cell and Passage Bio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lineage Cell position performs unexpectedly, Passage Bio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Passage Bio will offset losses from the drop in Passage Bio's long position.| Lineage Cell vs. MAIA Biotechnology | Lineage Cell vs. Armata Pharmaceuticals | Lineage Cell vs. Portage Biotech | Lineage Cell vs. Cadrenal Therapeutics, Common |
| Passage Bio vs. Black Diamond Therapeutics | Passage Bio vs. Revolution Medicines | Passage Bio vs. Stoke Therapeutics | Passage Bio vs. Cabaletta Bio |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Complementary Tools
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |